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Abstract 
Recent advances have provided evidence for the involvement of neutrophils in both innate 
and adaptive immunity, robustly challenging the old dogma that neutrophils are short-lived 
prototypical innate immune cells solely involved in acute responses to microbes and exerting 
collateral tissue damage. There is now ample evidence showing that neutrophils can migrate 
into different compartments of the lymphoid system where they contribute to the orchestration 
of the activation and/or suppression of lymphocyte effector functions in homeostasis and 
during chronic inflammation, such as autoimmune disorders and cancer. In support of this 
notion, neutrophils can generate a wide range of cytokines and other mediators capable of 
regulating the survival, proliferation and functions of both T and B cells. In addition, neutrophils 
can directly engage with lymphocytes and promote antigen presentation. Furthermore, there 
is emerging evidence of the existence of distinct and diverse neutrophil phenotypes with 
immunomodulatory functions that characterise different pathological conditions, including 
chronic and autoimmune inflammatory conditions. The aim of this review is to discuss the 
mechanisms implicated in neutrophil trafficking into the lymphoid system and to provide an 
overview of the immuno-regulatory functions of neutrophils in health and disease in the context 
of adaptive immunity.    
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Introduction 
Neutrophils are short-lived immune cells that are commonly accepted as being the first 
leukocyte sub-type to be recruited in large numbers from the blood circulation into inflamed 
tissues. Their migration through the cellular and matrix components of blood vessel walls is a 
tightly regulated process involving intricate cellular and molecular interactions, as summarised 
in recent articles [1-6]. This phenomenon is fundamental for an effective innate immune 
response against infections or acute injury, providing a host defence mechanism that clears 
tissues of invading pathogens, dead cells and potentially harmful debris. Neutrophil diapedesis 
also plays an important role in regulating the phenotype and activation state of emigrated 
neutrophils at sites of inflammation [7]. Key effector functions of neutrophils include 
phagocytosis and killing of intracellular or extracellular pathogens, tissue remodelling and 
secretion of chemotactic and immunomodulatory molecules that can further regulate the 
recruitment and activation of other pro-inflammatory leukocytes [8-11]. To facilitate these 
functions, activated neutrophils can also release a wide range of granular proteases and 
cytotoxic factors, as well as generate a host of reactive oxygen species. Whilst such 
capabilities are essential armoury for destroying microorganisms, they can also cause 
collateral damage to host tissues, rendering clearance of apoptotic neutrophils an essential 
component of resolving an inflammatory response [12,13]. Another form of cell death program 
for neutrophils is via NETosis, a dynamic process associated with the generation of neutrophil 
extracellular traps (NETs) [14-16]. NETs are generated through the release of decondensed 
chromatin and granular enzymes into the extracellular space surrounding leukocytes as 
means of controlling the dissemination of infectious microorganisms [14,17,18]. Whilst the role 
of NETs in the direct killing of pathogens remains contentious [14,19,20], there is strong 
evidence to indicate that the formation of NETs in vivo can be detrimental to the host. 
Pathological induction of NETs, such as that induced under conditions of sterile injury (e.g. 
ischemia-reperfusion injury) can also cause tissue damage and indeed NETosis has been 
implicated to the pathogenesis of a wide range of non-infectious inflammatory disorders [21-
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24]. Collectively, excessive recruitment, activation and/or inefficient clearance of infiltrated 
neutrophils is now categorically associated with the development of numerous acute 
pathological conditions such as myocardial infarction, stroke and tissue damage caused by 
ischemic insults [22,25,26] and there is now a growing interest in the pathogenic potential of 
neutrophils in chronic conditions such as cancer [27-29].  Furthermore, the association of 
neutrophils with multiple autoimmune disorders (e.g. rheumatoid arthritis, lupus, multiple 
sclerosis, Crohn’s disease and vasculitis) [21,30-34] has invigorated the interest in neutrophils 
as potential players in regulation of adaptive immunity.   
Nearly 50 years ago, whilst studying the trafficking of immune cells in sheep, Smith and 
colleagues discovered that the neutrophil “endgame” was not limited to apoptosis within 
inflamed tissues but that these cells could be detected in the peripheral lymph of the animals 
[35]. The authors speculated that this response provided a means for neutrophils to recirculate 
back into the blood, as opposed to contributing to adaptive immune responses taking place in 
the draining lymph nodes (LNs). This hypothesis was upheld for a long time due to the difficulty 
in culturing neutrophils for prolonged periods in vitro and the general and well-accepted 
assumption that the neutrophil life expectancy in the blood circulation did not exceed one day. 
However, advancements in techniques for tracking neutrophils in vivo, and the overall better 
understanding of neutrophil biology, have unequivocally demonstrated that neutrophils can 
exhibit prolonged survival both in vitro and in vivo [36]. For example, whilst human neutrophils 
are reported to exhibit a blood circulation period of up to 5 days [37], cytokines such as GM-
CSF [38,39], bacteria-derived products [40], hypoxic conditions [41] and diapedesis through 
blood endothelium [42,43] can protect neutrophils from rapid cell death. Such findings have 
led to greater acceptance of neutrophils as regulators of the adaptive immunity as supported 
by a large body of evidence demonstrating that neutrophils can migrate into secondary 
lymphoid organs such as lymph nodes (LNs) during bacterial and parasitic infections as well 
as during vaccination challenge protocols [44-47]. These works also reported on the ability of 
neutrophils to secrete numerous immunomodulatory molecules affecting lymphocytes [48-50] 
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as well as to directly interact with lymphocytes acting as antigen presenting cells (APCs) [51-
56]. Collectively there is now a renewed interest in models related to neutrophil trafficking into 
the lymphoid system and the pathophysiological consequences of this response, concepts 
that are reviewed below.  
 
Neutrophil trafficking to lymphoid tissues 
Neutrophil migration to lymphoid organs was first demonstrated in animal models through 
localising neutrophils within the draining LNs of tissues infected with microorganisms or 
following vaccine challenge [44-47,57]. The development and use of advanced imaging tools, 
such as intravital confocal microscopy, in conjunction with genetically modified animals 
exhibiting fluorescently-tagged neutrophils (e.g. LysM-GFP-ki mice), enabled detailed analysis 
of the dynamics of neutrophil-lymphatic vessel interactions as well as the role of specific 
molecular cues involved in this process (Table 1). These studies provided direct evidence for 
neutrophils migrating to LNs via afferent lymphatics present in inflamed tissues. Interestingly, 
this trafficking response was rapid (within 6-12hrs post insult) and transient as very few 
neutrophils could be detected in the LNs past 48hrs [46,57]. The first molecular pathway linked 
with this response involved CCR7 and its cognate ligands CCL21 and CCL19 [45]. Importantly, 
the work of Beauvillain and colleagues demonstrated the presence of intracellular stores 
(possibly secretory vesicles) of CCR7 in both human and murine neutrophils isolated from the 
blood and bone marrow, respectively. Interestingly, whilst CCR7 was almost un-detectable on 
the cell surface of neutrophils, the introduction of a purification step to enrich the neutrophil 
population in vitro enabled the detection of the molecule on the membrane. These findings 
suggested that priming of leukocytes was essential for the trafficking of CCR7 from 
intracellular stores to the cell membrane. Indeed, stimulation of human neutrophils with the 
cytokine GM-CSF could promote their migration towards a CCL21/CCL19 chemotactic 
gradient in vitro, a response that was potentiated by LPS or IL17. In vivo, we and others have 
demonstrated that upon immunisation with complete Freund’s adjuvant (CFA), CCR7 deficient 
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mice have reduced numbers of neutrophils migrating into tissue-associated lymphatic 
capillaries and into draining LNs, as compared to wild-type control littermates [45,57]. Our 
study also provided evidence that immunisation of the animals with CFA induced the local 
release of endogenous TNF, a response essential for the control of neutrophil entry into 
lymphatic capillaries in a CCR7-dependent manner. Furthermore, the trafficking of CCR7-
deficient neutrophils through afferent lymphatic vessels was completely suppressed in TNF-
induced inflammation [57]. Interestingly, significant CCR7 expression was detected on the cell 
surface of tissue-infiltrated neutrophils but not on cells from the blood circulation, or on tissue-
infiltrated neutrophils deficient in TNF receptors (both TNFRI and TNFRII). Collectively, these 
findings provide compelling evidence to indicate the necessity of priming for neutrophil 
migration into the lymphoid system and identify tissue-derived TNF as a key modulator of in 
vivo expression and function of CCR7 on neutrophils. Other studies have suggested that the 
CXCR4/CXCL12 axis is critical for neutrophil entry into the lymphatic system [53,58]. CXCR4 
is a chemokine receptor expressed at low levels on the surface of mature healthy neutrophils; 
but this molecule is upregulated on the membrane of aged neutrophils, a response associated 
with the egress of senescent neutrophils from the circulation [59-61]. In a study using a murine 
model of S. aureus infection, a specific inhibitor of CXCR4, AMD3100, was shown to 
significantly reduce the migration of neutrophils into afferent lymphatic vessels and draining 
LNs, whilst CCR7-deficient neutrophils exhibited normal trafficking to the lymphatic system 
[53]. Similar results were obtained in a mouse model of immunisation associated with pre-
activation of neutrophils with immune complexes [58]. Differential involvement of distinct 
chemokine axes in regulating neutrophil entry into the lymphatics might depend on the 
inflammatory models used, the degree of activation of neutrophils or the potential existence of 
yet not described tissue-specific mechanisms. Another chemokine implicated in human 
neutrophil migration into the lymphatic system is the prototypical neutrophil chemoattractant 
CXCL8. A study by Rigby and colleagues recently demonstrated that human dermal lymphatic 
endothelial cells (LECs) can secrete this chemokine and promote the migration of human 
neutrophils through LEC monolayers in vitro [62]. Similarly, isolated LECs from murine skin 
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exhibited enhanced gene expression of CXCL1 (a homologue of human CXCL8) upon 
stimulation [63]. However, blockade of CXCL1 protein, or its receptor CXCR2, had no effect 
on murine neutrophil recruitment to lymphatic vessels in vivo [53,57], highlighting potential 
discrepancies between putative in vivo and in vitro – and species - scenarios. In addition to 
chemokines, adhesion molecules such as ICAM-1 and VCAM-1 have been reported to be 
expressed by stimulated LECs and to support human and mouse neutrophil-lymphatic vessel 
interactions via binding to leukocyte β2 integrins (e.g. Mac-1) both in vitro and in vivo 
[53,57,62]. For instance, Mac-1/ICAM-1 interaction is critical for the attachment and crawling 
of murine neutrophils along the luminal aspect of lymphatic endothelium in vivo [57]. Similarly, 
Mac-1 blockade inhibited the entry of neutrophils into lymphatics of mouse skin that had been 
locally injected with bacteria [53] whilst another neutrophil-expressed integrin, LFA-1, is 
apparently dispensable for neutrophil intravasation into lymphatic vessels [58].  
Several studies have also demonstrated the capacity of blood circulating neutrophils to enter 
lymph nodes via high endothelial venules (HEVs) during infection, post immune complex 
activation and antigen sensitisation [53,58,64]. To date the only chemotactic axis described to 
be important for the migration of neutrophils through HEVs is CXCR4/CXCL12 axis, whilst a 
role for CCR7 and its cognate ligands CCL21/CCL19 have been completely ruled out [53,58]. 
Other molecules associated with neutrophil-HEV interactions are P- & L-selectins and their 
cognate ligand PSGL-1 as well as endothelial cell ICAM-1 and leukocyte integrins Mac-1 and 
LFA-1 [53,58].  
Collectively, there is now ample evidence to demonstrate the capacity of neutrophils to migrate 
during inflammation into LNs via two distinct routes, though the molecular pathways of such 
events require further exploration. Nevertheless, the fact that LN neutrophils can originate 
from either the blood circulation or inflamed tissues suggests potential differential modes of 
neutrophil-mediated regulation of the adaptive immunity. The following section discusses the 
immuno-modulatory functions of neutrophils in the context of lymphocyte activation. 
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Neutrophil regulation of lymphocyte functions 
Recent advances in neutrophil biology, including studies detailed in the previous section, have 
acknowledged these cells as key players at the interface of innate and adaptive immunity in 
both physiological homeostasis and pathological inflammation. The rapid and transient nature 
of their trafficking to LNs, with a dwelling time in these organs not exceeding 2-7 days following 
an initial inflammatory insult [53,64], has led to the hypothesis that neutrophils can facilitate 
the transport of pathogens and antigens into LNs. It is considered that the latter are 
subsequently transferred to resident DCs and macrophages already present in secondary 
lymphoid organs through engulfment of neutrophil-derived vesicles (e.g. apobodies, 
exosomes or micro-vesicles). Furthermore, it is envisaged that through this cascade of events 
macrophages and conventional APCs such as DCs, can process and present exogenous 
antigens to lymphocytes [46,47]. This concept is supported by the detection of apoptotic 
neutrophils within LNs of S.aureus infected animals [53]. In addition to this notion, it is now 
clear that activated neutrophils can secrete numerous immune modulatory molecules that can 
directly stimulate the recruitment, activation and functions of lymphocytes [48-50]. More 
importantly, neutrophils can impact the regulatory functions of lymphocytes via direct 
neutrophil-lymphocyte interactions and antigen presentation [65]. For example, several 
studies have demonstrated the existence of the so-called neutrophil-DC hybrids, an activated 
neutrophil sub-type that exhibit characteristics of DCs (e.g. expressing MHC-II CD80 & CD86) 
and capable of presenting exogenous antigen to both CD4+ and CD8+ T lymphocytes in vivo 
and in vitro [51,66-68]. This phenomenon was confirmed by confocal imaging that showed the 
dynamics of cell contacts between neutrophils and lymphocytes in mouse models of infection 
and immunisation [46]. In humans, neutrophils can also stimulate the antigen-specific 
proliferation of both naïve and memory T cells through MHC-II expression [69]. Furthermore, 
neutrophils can positively and directly modulate B cell activation, survival and differentiation 
by mean of secretion of cytokines such as B-cell-Activating Factor of the tumor necrosis factor 
Family (BAFF) [70] and A Proliferation-Inducing Ligand (APRIL) [71]. Whilst neutrophils are 
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not usually seen in the germinal centres of LNs, a subpopulation has been found in the peri-
follicular areas and marginal zone of the spleen in both humans and mice [72,73]. These cells, 
termed B-helper neutrophils, have been reported to induce T-cell independent production of 
IgG and IgA (following immunoglobulin class switching) via the production of large amount of 
BAFF, APRIL, CD40L and interleukin-21. B helper neutrophils may therefore represent a 
central mechanism for enhancing antibody production and effective humoral responses in a 
T-cell independent manner [74-77]. Direct Interactions between neutrophils and B cells have 
also been observed in real time in lymph nodes of S.aureus infected animals [64].  
In recent years, the homogeneity of neutrophil population has become increasingly 
questionable, with detection of neutrophils exhibiting distinct functions and profiles leading to 
the concept of different subsets [78-81]. Several studies have indeed demonstrated that 
alternatively activated and/or HEV-recruited neutrophils can regulate the adaptive immune 
response by inhibiting B and T lymphocyte responses, in particular in the context of antibody 
production during vaccination challenge and infections [46,53,64,82,83]. Whilst the 
mechanisms associated with such functions are not fully understood, neutrophil suppressive 
properties on T lymphocyte activities involve the release of reactive oxygen species, nitric 
oxide or Arginase 1 in close vicinity of targeted lymphocytes [84,85]. Neutrophils can also 
directly inhibit T cell functions through cell-cell interactions in a Mac-1 or PD-L1 dependent 
manner during HIV infections, systemic endotoxemia and cancer [86-89]. Furthermore, whilst 
neutrophil depletion can increase the production of antigen-specific IgG and IgM, during 
S.aureus infection, B-helper neutrophils were shown to limit the production of IgM through 
release of TGF-β1 [64]. Finally, recent studies have also investigated the role of specific 
subtypes of neutrophils in the context of regulatory T cell (Treg) expansion and recruitment. 
For instance, an elegant study by Nadkarni and colleagues has demonstrated that neutrophils 
sensitised to pregnancy hormones promote the differentiation of a unique population of 
FOXP3+ CD4+ Tregs with a specific secretory phenotype (release of IL-10, VEGF and IL-17) 
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via the transfer of neutrophil-derived proteins such as forkhead box protein-1 to naive T cells 
[90].  
Taken together, there is now unquestionable evidence supporting neutrophil trafficking into 
the lymphatic system and the ability of these cells to regulate lymphocyte functions. These 
works have promoted more interest into the potential role of neutrophils in chronic disorders, 
including autoimmune diseases, as discussed below.  
 
Diversity of neutrophil phenotype and pathogenic potential in chronic and autoimmune 
diseases  
The notable and now widely accepted diversity of neutrophil functions has placed a spotlight 
on the potential existence of distinct neutrophil-subsets and their association with a broad 
range of pathologies (see examples in Figure 1). This includes subtypes of neutrophils that 
can exert stimulatory and suppressive effects on lymphocyte functions and the potential 
association of these cells to chronic disorders such as cancer, and autoimmune diseases, 
such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) [80,91,92]. One 
example relates to granulocytic myeloid-derived suppressor cells (PMN-MDSCs), detected in 
cancer patients, considered by some researchers as a subset of neutrophils [80,85,93,94]. 
This section reviews recent findings associated with neutrophil trafficking to lymphoid tissues 
in cancer and chronic inflammatory and autoimmune pathologies.    
 
The duality of neutrophil functions in cancer 
In human cancer, tumour-associated neutrophils have been classified as having anti-tumour 
(N1) and pro-tumour (N2) properties [91,95]. There is also a body of evidence supporting the 
presence of increased numbers of PMN-MDSCs in blood, within the tumour microenvironment 
and peripheral lymphoid organs (tumour-draining LNs and spleen) in this pathology in humans 
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and mice [96]. The dominant view is that neutrophils and PMN-MDSCs are important 
contributors to tumour progression through their ability to promote angiogenesis, proliferation 
and metastasis of cancer cells [93,94,97], as supported by experimental murine models of 
cancer [98]. Furthermore, N2 neutrophils and PMN-MDSCs have been shown to exhibit 
immunosuppressive properties via PD-L1-dependent immunosuppression of Th1 cell 
proliferation [88] and to promote the expansion and recruitment of regulatory T lymphocytes 
via the secretion of CCL17 [99-101]. Of note, a distinct sub-population of human neutrophils 
(exhibiting neutrophil-DC hybrid characteristics) has been discovered within the tumour-
microenvironment and draining LNs during the early stage of lung cancer [102,103]. These 
tumour-associated neutrophils were reported to induce efficient anti-tumour responses from 
memory CD8+ and CD4+ T cells in vitro and expressed CCR7 at their surface [104]. In support 
of these findings, a recent study has described the presence of CXCR2+ neutrophils exhibiting 
IL-6 secretory pro-inflammatory phenotype in the draining LN of gastric tumours [105]. At 
present, the literature lacks further detailed information regarding the route, mechanisms of 
migration and activity of such distinct populations of neutrophils during the development of the 
pathology in vivo. Yet, in the context of anti-tumour therapy, using a mouse model of colon 
carcinoma, Brackett and colleagues demonstrated that photodynamic therapy (PDT) was also 
associated with the rapid recruitment of neutrophils (i.e. within 4hrs post PDT) into tumour-
draining LNs through HEVs in an IL-17 and CXCR2/CXCL2 (but not CXCL1)-dependent 
manner [106,107].The authors also showed the importance of L-selectin and peripheral node 
addressin (PNAd) in neutrophil entry through HEVs in this model. Functionally, PDT has been 
associated with the development of neutrophil-dependent and tumour-specific primary and 
memory CD8(+) T cell responses through the direct induction of T lymphocyte proliferation 
and/or survival [108]. 
 
Neutrophils in chronic inflammatory and auto-immune disorders 
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Neutrophils with immuno-modulatory activities have also been detected in ageing, now 
regarded by some researchers as a low grade chronic inflammatory state (i.e. inflammageing). 
Accordingly, in aged mice neutrophils have been detected in high numbers in both T-cell and 
B-cell areas of the secondary lymphoid organs (i.e. LNs and spleen) [109]. The increased 
neutrophil trafficking to lymphoid organs was associated with enhanced life-span of the 
infiltrated neutrophils and their altered phenotype. Specifically, in healthy aged mice, lymphoid 
tissue neutrophils expressed an activated phenotype characterised by high levels of Mac-1 
and ICAM-1 and the concomitant synthesis of both pro-inflammatory and anti-inflammatory 
cytokines TNF and TGFβ, respectively. At present it is unclear what the role of these 
neutrophils is, but it is speculated that the atypical phenotype of lymphoid organ neutrophils 
could contribute to ageing-associated dysregulation of normal adaptive immune responses, 
e.g. in infections [109]. 
In autoimmune pathologies such as rheumatoid arthritis (RA), human synovial neutrophils 
express transcripts and proteins of MHC-II and co-stimulatory molecules CD80 and CD86 
during the early phase of the disease [110,111]. In vitro, freshly isolated synovial neutrophils 
are capable of stimulating a proliferative response in T-helper cells [111]. Whilst rather 
intriguing, such seminal studies did not demonstrate where (e.g. tissue localization) and when 
(e.g. phase of the disorder) during RA such neutrophil responses were functionally relevant to 
disease progression. Indeed, it would be important to elucidate if neutrophils can regulate T 
cell functions in RA in vivo within the secondary lymphoid organs. Related to this caveat, using 
a murine model of lupus, Bird and colleagues demonstrated that neutrophils can preferentially 
form close interactions with T cells in the early phase of the disease, whilst in the advanced 
stage, they mainly accumulate in B cell areas of the spleen, reminiscent of a B-helper 
phenotype [112]. Furthermore, transcriptome analysis demonstrated that neutrophils exhibited 
high expression of PD-L1, TGFβ and IL-1RA during the early disease phase. The 
immunosuppressive activity of neutrophils during this period was confirmed by the negative 
effect of neutrophil depletion on disease progression, germinal centre formation and 
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production of anti-double strand DNA antibodies. Conversely, during the late phase, 
neutrophils enriched in splenic B-cell regions increased their expression of TNF and BAFF, 
indicating that they may contribute to the expansion of auto-reactive B lymphocytes during 
disease progression [112]. Interestingly, B-helper neutrophils have been shown to be more 
susceptible to NETosis [73] and hence it has been suggested that, due to their localization 
and specific phenotypic characteristics, these cells may promote the expansion and survival 
of auto-reactive B cells. A role for B-helper neutrophils in supporting adaptive autoimmune 
responses has indeed been reported in many autoimmune disorders, including, RA, SLE and 
in anti-neutrophil cytoplasmic antibody-associated  (ANCA) vasculitis [72]. The mechanism of 
action of these neutrophils is not completely understood but their enhanced capacity to 
generate NETs was suggested to provide an abundant source of auto-antigens characteristic 
of these pathologies [17,113-115]. Supporting this concept, a recent study by Gestermann 
and colleagues demonstrated that NET components could directly activate memory B cells 
through TLR9 stimulation, leading to the production of pathogenic autoantibodies in a T cell-
independent manner [116]. Moreover, NETs can also stimulate plasmacytoid dendritic cells to 
secrete interferon-α which in turn, promotes NETosis of neutrophils. This cascade perpetuates 
a vicious cycle that can be observed in pathologies such as vasculitis, SLE, psoriasis, and 
type-1 diabetes [117-120]. 
The number of PMN-MDSCs have also been reported to increase in RA and SLE patients 
[121-123] as well as in several experimental animal models of lupus [124], collagen-induced 
arthritis [125], experimental autoimmune encephalomyelitis (EAE) [126], type-1 diabetes and 
inflammatory bowel disease [127,128]. Whilst many studies have correlated MDSCs with 
disease severity, their role in regulating lymphocyte responses remains controversial [129]. 
Indeed, whilst in RA, SLE and EAE, PMN-MDSCs have been shown to inhibit both proliferation 
of T helper-cells and their production of cytokines (e.g. interferon- and IL-2) in an arginase-
1-dependent manner, these cells also produce pro-inflammatory cytokines (e.g. IL-1 and 
TNF). The latter can promote the differentiation of naïve T lymphocytes into Th17 cells, 
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suggesting that in the disease inflammatory context, PMN-MDSCs can exhibit a pathogenic 
phenotype [122,130,131].  
Overall, whilst the current literature supports the concept of neutrophils orchestrating a 
pathogenic response during autoimmune and chronic inflammatory disorders, further 
investigations are required to determine if and how neutrophil trafficking into lymphoid organs 
might be contributing to the pathoetiology of these diseases.  
 
 Conclusion and perspectives 
In addition to their essential role in protecting the host against acute harmful insults, recent 
studies have identified a broader role for neutrophils in both physiological and pathological 
immunity, and hence the development of numerous chronic and autoimmune inflammatory 
disorders. Specifically, it is now clear that, despite being short-lived as compared to other 
immune cells, neutrophils can traffic into lymphoid tissues and contribute to shaping key 
adaptive immune responses. As such, current evidence supports the notion that in addition to 
dendritic cells and macrophages, neutrophils can act as a cellular bridge between innate and 
adaptive immunity in both health and disease. Whilst our understanding of the mechanisms of 
neutrophil trafficking and functions into lymphoid tissues are yet to be fully investigated, it is 
now accepted that depending on the nature, duration or the site of the insult, neutrophils can 
enter the lymphatic system by using both afferent lymphatic vessels as well as venular portals 
within LNs. Once in secondary lymphoid organs, neutrophils can act as immune-modulatory 
cells through cytokine production and via direct cell-cell interaction with other immune cells. 
Accordingly, neutrophils can orchestrate elaborate cellular and humoral responses as well as 
exert regulatory effects on lymphocyte functions. The development of new technologies 
applied to investigate the dynamics of neutrophil behaviour, phenotype and trafficking in both 
patient samples ex vivo and in animal models of inflammation in vivo has led to the 
identification of different subtypes of neutrophils with distinct regulatory functions in health and 
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disease. It is still debated if neutrophil subsets might represent an acquired phenotype, and/or 
level of activation through environmental molecular cues, or are in fact ontogenically separate 
cell populations. Irrespective of this, renewed interest in this phenotypic diversity and 
associated varied effector functions, in conjunction with better understanding of the 
spatiotemporal localisation of neutrophils is opening challenging research opportunities. In 
particular such works could pave the way towards addressing outstanding questions regarding 
the diverse functions of neutrophils during the development of autoimmune pathologies. Most 
importantly, association of different neutrophil subtypes with the pathogenesis of defined 
disorders has the potential for stratifying patients in terms of disease severity as well as identify 
new therapeutic targets in chronic and autoimmune conditions and cancer. 
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Figure 1: Neutrophils and the regulation of the adaptive immune response in diseases 
Neutrophils have been implicated in the regulation of T and B cell activities in many 
pathological scenarios including inflammageing, cancer, and autoimmune disorders such as 
rheumatoid arthritis and systemic lupus erythematosus. Neutrophils can both stimulate and 
immunosuppress lymphocyte functions through various mechanisms due to the plasticity of 
their phenotype, localisation and environmental priming. For instance they can secrete 
activating cytokines or act as antigen presenting cells to stimulate lymphocyte proliferation 
and auto-antibody production (e.g. via NETosis). In contrast, other subtypes of neutrophils 
have been shown to directly inhibit T cell activation through the release of TGFβ, nitric oxide 
(NO), arginase-1 (Arg-1) as well as through the expression and direct engagement of PD-L1 
with T cells.  
Table 1: Molecules implicated to neutrophil migration into the lymphoid system. 
 
 
 
a shown in humans 
b shown in mouse models 
Molecule Surface expression 
Role in entry via 
lymphatic 
capillaries 
Role in entry via 
high endothelial 
venules 
Inflammatory model (when relevant) References 
CCR7 
 Low neutrophil surface expression necessitating 
priming: 
 in vitro  (GM-CSF/IL-17/LPS a or TNF b) 
 in vivo (post-extravasation, TNF-dependent b) 
 Expressed on tumour-associated neutrophil N1 type a 
Yes but depends 
on the nature of 
the reaction 
No 
 In vitro stimulation a 
 Immunisation (CFA) b 
 TNF-induced inflammation b 
 Early lung tumour a 
[45], [53], 
[57], [107] 
CXCR4 
 Low surface level on mature neutrophils 
 High surface level on aged neutrophils 
Yes, 
(but depends on 
the nature of the 
reaction 
Yes 
 S.aureus infection b 
 Immunisation with immuno-complex activation b 
 Immunisation (CFA) b 
[53], [57], 
[58] 
CXCR2 High levels on mature naïve neutrophils 
Yes, in vitro  
No, in vivo 
in vivo during PDT 
 In vitro stimulation of dermal LECs a 
 S.aureus infection b 
 Immunisation (CFA) b 
 Photodynamic Therapy in cancer (PDT) b 
[53], [57], 
[62], [107] 
CD54 
(ICAM-1) 
Up-regulation on LVs and LECs upon inflammation (TNF 
dependent) 
Yes, 
(promote adhesion 
and luminal 
crawling) 
Yes 
 S.aureus infection b 
 Immunisation, TNF-induced inflammation b 
 Immunisation with immuno-complex activation b 
 In vitro stimulation of dermal LECs a 
[53], [57], 
[58], [62] 
CD11b 
(Mac-1) 
High expression on all neutrophils 
Yes,  
(promote adhesion 
and luminal 
crawling) 
Yes 
 S.aureus infection b 
 Immunisation, TNF-induced inflammation b 
 Immunisation with immuno-complex activation b 
 In vitro stimulation of dermal LECs a 
[53], [57], 
[58], [62] 
CD11a 
(LFA1) 
Expressed on all neutrophils Rarely Yes 
 S.aureus infection b 
 Immunisation with immuno-complex activation b 
[53], [58] 
CD62L 
(L-selectin) 
Expressed on neutrophils, shed upon 
stimulation/extravasation 
No Yes 
 S.aureus infection b 
 Immunisation with immuno-complex activation b 
 Photodynamic Therapy in cancer b 
[53], [58], 
[107] 
CD62P 
(P-selectin) 
Endothelial selectin, upregulated upon stimulation of ECs Not Tested Yes  Immunisation with immuno-complex activation b [58] 
CD62E 
(E-selectin) 
Endothelial selectin, upregulated upon stimulation of ECs in vitro only Yes  In vitro stimulation of dermal LECs a [58] 
CD168 
(PSGL-1) 
Selectin ligand expressed by both LECs and neutrophils No Yes 
 S.aureus infection b 
 Immunisation with immuno-complex activation b 
[53], [58] 
PNAd 
(Peripheral Node 
Addressin) 
Expressed on HEVs No Yes 
 S.aureus infection b 
 Immunisation with immuno-complex activation b 
[53], [58] 

